Shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) have received a consensus recommendation of “Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $2.50.

A number of research firms recently issued reports on RTTR. Zacks Investment Research upgraded shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research report on Thursday, October 26th. Roth Capital set a $2.00 target price on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 23rd. Finally, HC Wainwright dropped their target price on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a research report on Monday, October 23rd.

Ritter Pharmaceuticals (RTTR) remained flat at $$0.34 during trading on Friday. 242,275 shares of the company’s stock traded hands, compared to its average volume of 1,543,179. Ritter Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.14). equities research analysts expect that Ritter Pharmaceuticals will post -0.66 earnings per share for the current year.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. lifted its position in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,409 shares of the biotechnology company’s stock after acquiring an additional 76,046 shares during the quarter. KCG Holdings Inc. owned approximately 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent reporting period. 2.19% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Ritter Pharmaceuticals, Inc. (RTTR) Given Consensus Recommendation of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/19/ritter-pharmaceuticals-inc-rttr-given-consensus-recommendation-of-buy-by-analysts.html.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.